Can you introduce me to Vivactis in a few words or in a few figures?
Vivactis is a company that was founded in 2003 in France and quickly developed inclinations for international markets. Thanks to partnerships, in particular with Belgium, the company has been able to establish itself in the European markets and since 2018 this development has accelerated considerably towards the Asian, Eastern European and North and South American markets.
Vivactis is the largest independent consulting group in the world that offers integrated services throughout the value chain of a molecule or a device. Its teams provide strategic consulting services with high medical added value to healthcare players around the world, such as pharmaceutical, biotech, medical technology companies, scientific societies, associations, etc. The Vivactis group network is currently present in more than 25 countries around the world, with a presence in the main markets of the European Union.
Due to their 100% care vocation, the collaborators of the Vivactis network, multinational and multicultural, are widely recognized and appreciated for their scientific experience. Global, pan-European and local campaigns for pharmaceuticals, biotechnology, medical devices, medical nutrition and consumer health are at the core of Vivactis’ activities.
What are the prospects for future innovation in the medical world?
As an expert in healthcare communication consulting, our way of communicating is very specific. If before the way of communicating was focused on the product and its results in market share, today the board’s discourse is no longer the same.
When a molecule is going to change the therapeutic landscape and is going to have an impact on the health professional, the patient, the caregivers and the environment, the approach is necessarily more global. The development of the molecule requires the support of these patients and the creation of the network in their ecosystem. It is in this today that we position ourselves innovatively through an ethical approach.
How are developments in your market affecting your business?
In health, the approaches are changing. We were very focused on CURE (the therapeutic management of the disease) then we went from CURE to CARE (the dimension of care); today, the 2 dimensions overlap. A player in the healthcare industry can no longer be content to only communicate about his latest therapeutic innovation. It must be part of a more holistic approach to the patient, to consider not only their course of care, but also their life course.
As experts in health communication consultancy, we have been able to evolve in this direction and accompany our clients in this paradigm shift. Sometimes a step ahead, sometimes out of step and sometimes too ambitious in relation to the maturity of the market. Adaptability is our daily challenge. The key is likely to be listening to the needs of all stakeholders: industries, healthcare professionals, patients and carers, but also regulatory authorities. It is through the mobilization and commitment of all that we will co-build the models of tomorrow.
How would you define your company’s values and commitments?
The structure of the group makes Vivactis in France an independent and human-sized company of 60 people. This notion of human value is very important to us.
Our commitment is to contribute to the “better life” of patients. This is our leitmotiv. Even if our main client remains the pharmaceutical industry, which communicates with a core target of “health professionals”, we never lose sight of the fact that the end user is still the patient.
To contribute to this “better living”, the professional experience and life experience of each employee gives us the opportunity to get involved in all kinds of medical and social causes and positively influence the paths of life.
We invest as much in access to innovative medicines for the greatest number, the recognition of rare diseases and the well-being of the patient.
This content was produced with SCRIBEO. The BFMBUSINESS editorial team was not involved in the production of this content.
Source: BFM TV
